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Background: Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer disease, MALT
lymphoma, and adenocarcinoma of the stomach. The reported prevalence of H. pylori in the adult population
in Turkey is 67.6% 81.3%. A national meta-analysis showed that the average H. pylori eradication rate with
proton pump inhibitor-based triple regimens in Turkey had decreased from 84% in 1997 to 55.3% in 2004,
suggesting a need to evaluate alternative regimens.
Materials and methods: The study was a prospective, single-center trial with a parallel group design. After the
selection procedure, consecutive out-patients were assigned to one of six study groups using random sampling
numbers. All patients received amoxicillin 1,000 mg b.i.d. and clarithromycin 500 mg b.i.d. along with
ranitidine bismuth citrate 400 mg b.i.d., or omeprazole 20 mg b.i.d., or lansoprazole 30 mg b.i.d., or
rabeprazole 20 mg b.i.d., or pantoprazole 40 mg b.i.d., or esomeprazole 40 mg b.i.d. for 14 days.
Results: When we look at the eradication rates of the treatment groups, only two groups (ranitidine bismuth
citrate and rabeprazole groups) had eradication rates greater than 80%, both at intention to treat and per
protocol analyses. The other four groups (omeprazole, lansoprazole, pantoprazole, and esomeprazole groups)
showed statistically significant lower eradication rates both at intention to treat (between 57.6 and 66.7%) and
per protocol (between 60.3 and 72.1%) analyses when compared with ranitidine bismuth citrate and
rabeprazole groups (pB.05).
Conclusion: Ranitidine bismuth citrate and/or rabeprazole based triple therapies must be preferred for the
first-line treatment of H. pylori infection.
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bismuth citrate
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H
elicobacter pylori (H. pylori) infection is the
main cause of gastritis, gastroduodenal ulcer
disease, and mucosa associated lymphoid tissue
lymphoma and adenocarcinoma of the stomach. Pre-
valence of H. pylori infection in adults varies in different
parts of the world depending on the social and economic
standards of the population. While the prevalence among
the middle-aged population in developing countries is
about 80%, it is only 20% 50% in developed countries (1,
2). The reported prevalence of H. pylori in the adult
population in Turkey is 67.6% 81.3% (3 5). The treat-
ment of H. pylori is still a big challenge in the era of rising
antibiotic resistance. The Maastricht III consensus report
recommended proton pump inhibitor (PPI) or ranitidine
bismuth citrate (RBC) based triple regimen with clari-
thromycin and amoxicillin or metronidazole as first-line
therapy (6). The strong inhibition of gastric acid secretion
with PPIs made it the treatment of choice for many
clinicians. Therefore, standard triple therapies containing
a proton pump inhibitor and two antibiotics are the most
commonly used treatments for H. pylori eradication in
clinical practice. Consensus conferences have recom-
mended therapeutic regimens that achieve H. pylori
cure rates higher than 80% on an ‘intention-to-treat’
(ITT) basis (6, 7). However, during the last few years,
several studies have reported ITT eradication rates lower
than 75% (8 11) and even lower than 50% (12, 13) with
PPI-based regimens. A national meta-analysis showed
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triple regimens in Turkey had decreased from 84% in
1997 to 55.3% in 2004 (14), suggesting a need to evaluate
alternative regimens.
In this study, we aimed to investigate the current
success rate with 2 weeks of RBC-based and PPI-based
triple therapy regimens for eradication of H. pylori.
Patients and methods
The study was a prospective study including consecutive
H. pylori positive dyspeptic and peptic ulcer patients
referred to our gastroenterology clinic. During endo-
scopy, two antrum and two corpus biopsies were taken
for histological examination and, in addition, two antrum
biopsies were taken for rapid urease test. A patient was
considered to be infected when both tests (histology and
rapid urease test) were found positive. The exclusion
criteria were under 18 years of age, pregnancy, presence
of clinically significant comorbidities (insulin dependent
diabetes mellitus, neoplastic diseases, coagulopathies and
severe hepatic, renal or cardiorespiratory diseases), pre-
vious gastric surgery, known allergies to any of the drugs
used in the study, and previous H. pylori eradication
therapy. The protocol was approved by the local ethical
committee and informed consent was obtained from all
of the patients.
The study was a single-center trial with a parallel group
design. After the selection procedure, consecutive out-
patients were assigned to one of six study groups using
random sampling numbers. We put six cards with
numbers between one and six on them in a pocket, then
the patient picked one of them. When all of the cards
were picked, we put them back into the pocket and
started the picking again. All patients received amox-
icillin 1,000 mg b.i.d. and clarithromycin 500 mg b.i.d.
along with RBC 400 mg b.i.d. (RBC-AC group), or
omeprazole 20 mg b.i.d. (OAC group), or lansoprazole 30
mg b.i.d. (LAC group), or rabeprazole 20 mg b.i.d. (RAC
group), or pantoprazole 40 mg b.i.d. (PAC group), or
esomeprazole 40 mg b.i.d. (EsAC group) for 14 days.
Patients were advised of the possibility of having a
metallic taste, nausea, and diarrhea during the treatment
period. Compliance was evaluated at the end of the
treatment by pill count and was considered good if more
than 90% of medication had been taken. H. pylori
eradication was defined as a negative
13C-urea breath
test (UBT) performed 6 8 weeks after completion of the
eradication therapy. The UBT was carried out by
operators unaware of therapy and patients’ past H. pylori
status.
Statistical analysis
The Chi-square test was used to determine the difference
in eradication between the groups. Both ITT and per
protocol (PP) analyses were performed. Independent t-
test was used for determination of difference in age and
two proportions test for the difference in gender, smok-
ing, and the use of aspirin and NSAIDs. A p-value less
than 0.05 was considered significant. All statistical
analyses were performed using the SPSS 13 software.
Results
There were 396 patients randomized for the study (66
patients for each of the six study groups). Seventeen
patients were dropped from the study (Table 1). Five
patients were stopped taking drugs because of side effects
(two allergies, two diarrhea, and one numbness). Five
patients were excluded from the study because of poor
compliance and seven patients lost to follow-up. When we
look at the characteristics (sex, age, smoking status, and
aspirin or NSAID usage) of the groups, we cannot detect
any statistical difference between the groups. Also, there
is no difference between the groups according to the
etiology, nearly one-fourth of the patients of all of the
groups had peptic ulcer disease and the rest had H. pylori
gastritis.
When we look at the eradication rates of the treatment
groups (Table 1), only two groups had eradication rates
greater than 80%, both at ITTand PP analyses. These are
the RBC-AC and RAC groups. The other four groups
(OAC, LAC, PAC, and EsAC groups) showed statistically
significant lower eradication rates both at ITT (between
57.6 and 66.7%) and PP (between 60.3 and 72.1%)
analyses when compared with the RBC-AC and RAC
group (pB0.05).
Table 2 shows eradication rates of the different
subgroups. We cannot detect any difference between
males and females, smokers or non-smokers, aspirin
users or non-users, NSAID users and non-users, and
lastly the peptic ulcer group and H. pylori gastritis group.
Discussion
The Maastricht III consensus report recommended PPI-
or RBC-based triple regimen with clarithromycin and
amoxicillin or metronidazole as first-line therapy (6).
Consensus conferences have recommended therapeutic
regimens that achieve H. pylori cure rates higher than
80% on an ITT basis (6, 7). However, recent studies from
many countries have reported the failure of these regi-
mens (8 13). A national meta-analysis showed that the
average H. pylori eradication rate with PPI-based triple
regimens in Turkey had decreased from 84% in 1997 to
55.3% in 2004 (14).
Bismuth exerts a direct bactericidal effect on H. pylori.
To date, no resistance to bismuth has been reported. The
RBC has been developed as a unique novel compound
that presents, on one hand, the antisecretory activity of
ranitidine and, on the other, the mucosal protective and
anti-H. pylori effects of certain other bismuth salts (15,
16). Furthermore, the frequency or the severity of adverse
Huseyin Alkim et al.
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(page number not for citation purpose)effects reported with PPI- and RBC-based regimens has
been similar. A meta-analysis showed that the efficacy of
RBC-based triple regimens was similar or even higher
than that based on PPIs, perhaps due to a synergistic
interaction of RBC with some antibiotics (17).
One recently published trial compared a 10-day
bismuth-based regime containing metronidazole, tetracy-
cline, and omeprazole (OBMT) against a 7-day course of
triple therapy with OAC. Eradication rates were 93.3%
with OBMT and 69.6% with OAC in the PP population
(pB0.001) and 79.8 and 55.4%, respectively, in the ITT
population (18). An older study that looked at a 14-day
OBMTregime had showed an eradication rate of 95% by
ITT analysis (19). An in vitro synergy between RBC and
clarithromycin or tetracycline against resistant H. pylori
strains makes the combination of these drugs more
logical than PPI-based H. pylori eradication therapies
as first-line treatment (20). Also, bismuth-based therapies
have an efficacy of 76% in second-line therapy on the
basis of pooled analysis (21). In Turkey, clarithromycin
resistance has reached to 50% (22). The eradication rate
of RBC-based triple regimens reported from Turkey
varies between 74.6 and 95.9%. In one of these studies,
an 80% eradication rate was reported in clarithromycin-
resistant cases with RBC, amoxicillin, and clarithromycin
(22). So our RBC-based triple therapy success rate was
consistent with the international and national results.
Our PPI-based triple therapy results were as expected
with the exception of rabeprazole-based triple therapy.
Rabeprazole can achieve optimal acid suppression since
the first administration and can maintain this advantage
in the following days of therapy. Moreover, rabeprazole
has the highest pKa ( 5.0, the pH at which a drug
becomes 50% protonated); hence, the molecule can be
activated at higher pH levels much faster than other PPIs.
Due to its peculiar catabolic pathway, i.e. a prevalent
metabolism through a non-enzymatic pathway, rabepra-
zole is less susceptible to the influence of genetic
polymorphisms for CYP2C19 (which encodes a member
of the cytochrome P450 superfamily), resulting in minor
influences on its pharmacokinetics and pharmacody-
namics (23). A recently done meta-analysis concluded
that the efficacy of first-line triple therapies based on
omeprazole and lansoprazole at the standard doses is
dependent on CYP2C19 genotype status, which appears
not to affect the efficacy of the regimens including
rabeprazole (24).
Antibiotics have varying stability at acid pH. Amox-
icillin is unstable at low pH, but its half-life is still 15
hours at a pH of 2. In contrast, clarithromycin is
particularly sensitive to degradation with acid and has
a half-life of less than 1 hour at pH 2 (25). Rabeprazole,
as we mentioned, provides reliable control of gastric acid
secretion, with more potent antisecretory activity than
that in other PPIs such as omeprazole and lansoprazole,
a more rapid rise in intragastric pH, and less effect of
CYP2C19 on its metabolism (23 26). So, the use of PPIs,
especially rabeprazole, in antimicrobial regimens that
contain clarithromycin is particularly important in pre-
venting degradation of clarithromycin by acid.
The H. pylori eradication rate by triple therapy based
on a PPI, amoxicillin, and clarithromycin is thought to be
affected by age, smoking habits, drug compliance, poly-
morphisms of the CYP2C19 gene, drug susceptibility,
and clarithromycin resistance (27). In particular, clari-
thromycin resistance is viewed to have a large effect on
Table 2. Eradication rates in different subgroups
Characteristic Group Total number Eradicated number (%)
Completion of study All patients
Completed study
396
379
272 (68.7%)
272 (71.8%)
Gender Male
Female
214
165
147 (68.7%)
125 (75.8%)
Smoking Yes
No
147
232
103 (70.1%)
169 (72.8%)
Aspirin use Yes
No
53
326
40 (75.5%)
232 (71%)
NSAID use Yes
No
75
304
50 (73.3%)
217 (71.4%)
Peptic ulcer H. pylori gastritis *
*
94
285
68 (72.3%)
204 (71.6%)
Note: Statistically significant difference was not present between the groups.
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4
(page number not for citation purpose)
Citation: Libyan J Med 2011, 6: 8412 - DOI: 10.3402/ljm.v6i0.8412the eradication rate. That arises from the big deteriora-
tion in eradication rate from about 80.6 to 98.3% for
clarithromycin susceptible bacteria to 0% 33.3% for
clarithromycin resistant bacteria (28). On the other
hand, the eradication rate for triple therapies is reported
to depend on the degree of acid secretion suppression, in
addition to clarithromycin resistance, and the importance
of acid secretion suppression has also drawn attention
(29). It is thought that the PPIs ability to suppress acid
secretion affects the eradication more for clarithromycin-
resistant H. pylori. While the eradication rates in
omeprazole and lansoprazole groups decreased signifi-
cantly over time, no apparent decline in eradication rate
was seen for the rabeprazole group (27). Also, rabepra-
zole itself is indicated to possess antibiotic effects against
H. pylori and it might have helped as well.
In the current situation where prevalence of primary
resistance to clarithromycin increased, it was difficult to
ascertain the reasons why differences arose in the effec-
tiveness of H. pylori eradication by acid secretion-
suppressing agents and triple therapy based on a PPI.
However, the eradication rate for large-scale triple
therapy using rabeprazole is reported to be good and to
be ]90% in spite of an increase in the clarithromycin
resistance in recent years (30). But most of the studies
reported in the literature were from Japan and China.
There are two studies from Turkey reporting rabeprazole-
based treatment success. The first one was a national
report that detected 90% eradication rate with 14 days
rabeprazole, amoxicillin, and clarithromycin therapy in
10 patients (31). The second one was a modified
sequential therapy (rabeprazole and amoxicillin 7 days
followed by rabeprazole, metronidazole, and levofloxacin
for 7 days) that reported 82.5% ITT and 86.7% PP
eradication rates in the treatment of naive patients (32).
So together with these results we can suggest that when
using PPI-based triple therapy, it is more logical to prefer
rabeprazole. But before recommending routine use of
rabeprazole we have to test this on a larger scale, and also
in patients with documented clarithromycin resistant H.
pylori. The selection of a PPI should also be important in
first-line eradication today and we need to make it clearer
thereafter.
Ranitidine bismuth citrate emerged in 1991 as a highly
effective drug, but the lackof worldwide availability and a
fall in the product’s promotion have led to a limited use of
this valuable compound. Rabeprazole is the last devel-
oped and probably most potent PPI that have different
features (has the highest pKa between the PPIs, more
potent and rapid rise in intragastric pH, and less effect of
CYP2C19 polymorphism on its metabolism). In conclu-
sion, according to our results, RBC and/or rabeprazole-
based triple therapies must be preferred for the first-line
treatment of H. pylori infection.
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